NCT07306936

Brief Summary

The intra-articular injection is considered the first line of minimally invasive treatment in temporomandibular joint with internal derangement (TMJ-ID) patients who do not respond to conservative treatment. The single-needle technique arthrocentesis has emerged to add reliability, convenience, ease the performance of the procedure, and eliminate the need for multiple punctures the Aim of this study is to assess clinical applicability and therapeutic outcomes of computer guided single needle arthrocentesis with platelet rich plasma using Shepard's cannula, in comparison with conventional free-hand technique, in the management of disc displacement with reduction of the TMJ.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2025

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

December 13, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 29, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

December 29, 2025

Status Verified

December 1, 2025

Enrollment Period

8 months

First QC Date

December 13, 2025

Last Update Submit

December 13, 2025

Conditions

Keywords

temporomandibular disorderintra-articular injectioninternal derangementanterior disc displacementcomputer-assistedComputer-aided designcomputer-aided manufacturingsoftwareshepard cannula

Outcome Measures

Primary Outcomes (1)

  • objective assessment of joint function and mandibular excursion

    Clinical evaluation will be based on the Helkimo's clinical dysfunction index (Di), which is a part of the Helkimo index that provides an objective assesment of joint function and mandibular excursion. All patients will be assessed immediately post-operative, 1 and 3 months. Postoperative clinical evaluation values will be compared to the preoperative baseline preoperative values.

    3 months

Secondary Outcomes (1)

  • Duration of the Operation

    intraoperative

Study Arms (2)

Patients with TMJ ID + reduction managed with computer-guided single needle arthrocentesis

EXPERIMENTAL

Patients with TMJ ID + reduction managed with computer-guided single needle arthrocentesis in adjunct to PRP intra-articular injection.

Device: Computer-guided single needle arthrocentesis

Patients with TMJ ID + reduction managed with conventional free hand single needle arthrocentesis

PLACEBO COMPARATOR

Patients with TMJ ID + reduction managed with conventional free hand single needle arthrocentesis in adjunct to PRP intra-articular injection

Device: conventional free hand single needle arthrocentesis

Interventions

Patients with TMJ ID + reduction managed with conventional free hand single needle arthrocentesis in adjunct to PRP intra-articular injection.

Patients with TMJ ID + reduction managed with conventional free hand single needle arthrocentesis

Patients with TMJ ID + reduction managed with computer-guided single needle arthrocentesis in adjunct to PRP intra-articular injection

Patients with TMJ ID + reduction managed with computer-guided single needle arthrocentesis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with internal derangement according to Wilkes stage I and II.
  • Adult patients above 18 years old.
  • Patients who would not respond to conservative treatment as a first line of treatment

You may not qualify if:

  • Patients with Wilkes stage III, IV, V.
  • Patients suffering from any systemic diseases, platelets function disorders, fibrinogen deficiency.
  • History of mandibular fracture.
  • Lactating, pregnant or planning pregnancy women.
  • Patients receiving anticoagulation treatment or NSAIDS within 48 hours preoperatively, corticosteroid injection at treatment site within 1 month or systemic use of corticosteroids within 2 weeks.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Outpatient clinics of Faculty of Dentistry, Alexandria University, Egypt Alexandria

Alexandria, Alexandria Governorate, 21523, Egypt

Location

MeSH Terms

Conditions

Temporomandibular Joint Disorders

Condition Hierarchy (Ancestors)

Craniomandibular DisordersMandibular DiseasesJaw DiseasesMusculoskeletal DiseasesJoint DiseasesMuscular DiseasesStomatognathic Diseases

Study Officials

  • yehia El-Mahallawy, Phd

    Faculty of Dentistry, Alexandria University, Alexandria, Alexandria

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Sequentially numbered, opaque, sealed envelopes (SNOSE) allocation concealment method will be utilized. Each participant included in the study will be given a serial number that will be used in the allocation. These numbers will be written in identical sheets of paper with the group to which each participant is allocated and placed inside opaque envelopes carrying the respective names of participants. A trial independent personnel will be assigned the role of keeping the envelopes and unfolding them only at the time of the operation, so that the participant is allocated to a group which is concealed from the operator
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 13, 2025

First Posted

December 29, 2025

Study Start

April 1, 2025

Primary Completion

November 30, 2025

Study Completion

March 1, 2026

Last Updated

December 29, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

all data will be de-identified to protect the participant data. patients signed an informed consent for the use of their medical records and data for study

Locations